Edit Working Paper

user warning: Field 'wid' doesn't have a default value query: INSERT INTO watchdog (uid, type, message, severity, link, location, referer, hostname, timestamp) VALUES (0, 'access denied', 'profiles/162-80280/js/images/crest.png', 1, '', 'https://econ.ucalgary.ca/manageprofile/profiles/162-80280/js/images/crest.png', 'http://econ.ucalgary.ca/profiles/162-80280/js/images/crest.png', '136.159.190.101', 1715937519) in /mnt/web/drupal5-wcm/includes/database.mysql.inc on line 174.
user warning: Field 'wid' doesn't have a default value query: INSERT INTO watchdog (uid, type, message, severity, link, location, referer, hostname, timestamp) VALUES (0, 'access denied', 'profiles/1-7724374/css/images/crest.png', 1, '', 'https://econ.ucalgary.ca/manageprofile/profiles/1-7724374/css/images/crest.png', 'http://econ.ucalgary.ca/manageprofile/profiles/1-7724374/css/images/crest.png', '136.159.190.101', 1715937523) in /mnt/web/drupal5-wcm/includes/database.mysql.inc on line 174.

General Details

Title: *

WP Number: 2010-10

Abstract:

The problem of obtaining fair pricing for generic drugs has led to a series of regulatory measures in Canadian provinces. This paper offers a new way of thinking about the problems that need to be addressed, by considering three core components of the value chain of getting generic drugs to Canadians: litigation, production, and pharmacy services. The paper proposes that each component of this value chain should be paid for separately, using a royalty to reward successful litigation that benefits payers; a competitive market framework to pay for production; and a transparent, independent regulatory process to set dispensing fees for pharmacies.  This approach would enable the total expenditures to match costs, would enable provinces to set appropriate quality and convenience standards for pharmacy, and would provide a measure of predictability for investors.
The paper emphasizes that it is important to establish a separate mechanism for rewarding litigation that eliminates invalid patents. The savings to Canadians from such litigation exceeds one billion dollars annually. Without addressing the need to reward this valuable activity, it is dangerous for payers to drive down generic prices, since generic firms will lack incentives to invest in costly litigation. The paper also encourages governments to establish independent regulatory authorities to set fair fees for pharmacies by employing processes similar to those used in other price regulation agencies.

Length:

JEL Classification:

Keywords:

Date(s)

Created:

Format: 2024/05/17

Last updated:

Format: 2024/05/17

	Author	Weight

	Published as: If the publication is published using an alternate name enter it here

Loading...

Current Document: generic_pricing_policy_2010-Hollis.pdf

Upload File:

Cancel

top

Edit Working Paper

About the Faculty of Arts

About the U of C

Quick Links